[1]中国抗癌协会肿瘤介入专家委员会.经导管动脉灌注化疗药物应用原则——中国肿瘤介入专家共识[J].介入放射学杂志,2017,(11):963-970.
 Tumor Intervention Expert Committee of Chinese Anti- Cancer Association.Chinese tumor intervention expert consensus on the application principles of transcatheter arterial infusion chemotherapy[J].journal interventional radiology,2017,(11):963-970.
点击复制

经导管动脉灌注化疗药物应用原则——中国肿瘤介入专家共识()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年11期
页码:
963-970
栏目:
指南与共识
出版日期:
2017-11-25

文章信息/Info

Title:
Chinese tumor intervention expert consensus on the application principles of transcatheter arterial infusion chemotherapy
作者:
中国抗癌协会肿瘤介入专家委员会
Author(s):
Tumor Intervention Expert Committee of Chinese Anti- Cancer Association
关键词:
【关键词】 恶性肿瘤 经导管动脉灌注化疗 化疗药物
文献标志码:
A
摘要:
【摘要】 经导管动脉灌注化疗(TAI)是肿瘤介入治疗的重要手段之一,也是保证化疗在局部治疗中发挥最大抗癌效力的一个必要途径。TAI中药物选择既要遵循常规全身化疗基本原则,又要兼顾经导管区域性药物灌注特性。理论上静脉输注化疗药物均能经动脉灌注,但需经人体转化后才能起效的药物不适用于TAI。TAI是在肿瘤供血动脉内直接灌注药物,能克服部分静脉化疗无法通过的生理屏障,起到药物“首过效应”,从而显著提高肿瘤局部药物浓度,提高疗效。TAI后化疗药物同样会沿血液循环到全身,同时也起到全身化疗作用。TAI也会产生不良反应,相比全身化疗程度要轻微,对人体免疫功能损害亦较轻。TAI虽然适用于各种中晚期恶性肿瘤,但也必须严格把握适应证和禁忌证,即在选择用药时应谨慎、合理,争取在获得最大有效作用的同时减少不良反应。选择TAI药物时应根据以下用药原则:选择肿瘤敏感药物,选择原型起作用药物,首选浓度依赖型药物,联合应用不同作用机制药物,尽量避免药物毒性作用相同或对同一脏器毒性累加的药物,不得应用相互拮抗或相互发生不良化学反应的药物及溶剂配伍,严格执行特殊药物使用说明,给予适当剂量的化疗药物,注意化疗药物应用先后顺序,重视非抗肿瘤药物与化疗药之间相互作用,以及药物稀释浓度与容量。

参考文献/References:

[1] 王革芳, 程永德. 动脉灌注化疗的药物选择原则[J]. 介入放射学杂志, 2009, 18: 797- 800.
[2] 汤钊猷. 现代肿瘤学[M]. 第3版, 上海: 复旦大学出版社,2011: 375- 376.
[3] Ma T, Tan L, Shao H, et al. Direct to tumor: transarterial administration of gold nanoshells with enhanced targeting and photothermal therapy[J]. J Biomed Nanotechnol 2017[Epub ahead of print].
[4] 曹世龙. 肿瘤学新理论和新技术[M]. 上海: 上海科技教育出版社, 1997: 1010- 1011.
[5] 程永德, 程英升, 颜志平. 常见恶性肿瘤介入治疗指南[M]. 北京: 科学出版社, 2013: 72- 73.
[6] 王 珏, 程永德. 介入放射药物治疗学[M]. 北京: 科学出版社, 2009: 620- 623.
[7] 孙 莉, 于金明. 肿瘤化疗不良反应与对策[M]. 山东: 山东科学技术出版社, 2002: 157- 180.
[8] 梁 君, 陈元龙, 潘辉娟, 等. 以雷替曲塞为基础经动脉灌注化疗的安全性和有效性分析[J]. 影像诊断与介入放射学, 2013, 22: 436- 438.
[9] Wilson KS, Malfair- Taylor SC. Raltitrexed: optimism and reality[J]. Expert Opin Drug Metab Toxieol, 2009, 5: 1447- 1454.
[10] Hao MC, Yin XZ, Wang H, et al. Synthesis of anticancer drug raltitrexed[J]. Chin J Med Chem, 2007, 17: 368- 371.
[11] 孙 燕. 抗肿瘤药物手册[M]. 北京: 北京大学医学出版社, 2006: 20- 21.
[12] 孙 燕, 周济昌. 临床肿瘤内科手册[M]. 4版. 北京: 人民卫生出版社, 2003: 60- 73.
[13] 孙 燕, 周济昌. 临床肿瘤内科手册[M]. 4版. 北京: 人民卫生出版社, 2003: 46.
[14] 胡 胜, 臧爱华. 癌症治疗中药物相互作用[J]. 中国肿瘤, 2006, 15: 27- 30.
[15] 王程程, 彭 媛, 陈芙蓉, 等. 肿瘤联合化疗与用药顺序[J]. 中国药房, 2013, 24: 2070- 2071.
[16] 孟艳莉, 黎海亮, 郭晨阳, 等. 三氧化二砷经肝动脉化疗栓塞治疗多结节型或弥漫型原发性肝癌的临床研究[J]. 介入放射学杂志, 2015, 24: 680- 683.
[17] 中国医师协会介入医师分会. 注射用洛铂在原发性肝癌TACE治疗中的专家共识(2016版)[J]. 中华介入放射学电子杂志, 2016, 4: 1- 3.
[18] 高 嵩, 朱 旭, 杨仁杰. TACE联合奥沙利铂、 氟尿嘧啶、 亚叶酸钙经肝动脉化疗治疗中晚期肝癌[J]. 介入放射学杂志, 2012, 21: 377- 383.
[19] Liang KH, Lin CL, Chen SF, et al. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization[J]. Pharmacogenomics, 2016, 17: 353- 366.
[20] Zhao H, Zhang Y, Sun J, et al. Raltitrexed inhibits HepG2 cell proliferation via G0/G1 cell cycle arrest[J]. Oncol Res, 2016, 23: 237- 248.
[21] 阿布都外力?吾布力卡斯穆,迪里木拉提?巴吾冬, 任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J]. 介入放射学杂志, 2014, 23: 441- 445.
[22] 武中林, 古铁树, 康一鹤, 等. 精准TACE在原发性肝癌的应用[J]. 实用放射学杂志, 2016, 32: 933- 937.
[23] 乔彬彬, 虞希祥, 王舒婷, 等. TACE术中灌注氟尿嘧啶、奥沙利铂及吡柔比星治疗原发性肝癌的临床效果分析[J]. 介入放射学杂志, 2015, 24: 349- 353.
[24] 张璐西, 施海彬, 刘 圣, 等. TACE联合索拉菲尼治疗BCLC- C期肝细胞癌20例疗效分析[J]. 介入放射学杂志, 2014, 23: 954- 958.
[25] 顾 兵, 张 敏, 陈 双, 等. 两种三联动脉化疗栓塞方案治疗无法切除原发性肝癌临床对比研究[J]. 现代肿瘤医学, 2016, 24: 2565- 2568.
[26] 田 浩, 徐 浩, 王诗学, 等. 经肝动脉、 肠系膜上动脉双途径治疗原发性肝癌21例对照研究[J]. 介入放射学杂志, 2014, 23: 721- 724.
[27] Lorenz M, Staib- Sebler E, Gog C, et al. The status of regional long- term chemotherapy in liver metastasis[J]. Chirurg, 1999, 70: 141- 153.
[28] 李万刚, 崔 静, 王建军, 等. 术前支气管动脉灌注化疗IIIa(N2)期非小细胞肺癌[J]. 介入放射学杂志, 2015, 24: 160.
[29] Jeon YW, Ahn YE, Chung WS, et al. Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells[J]. Tumour Biol, 2015, 36: 6349- 6359.
[30] Mohammadinejad P, Arya P, Esfandbod M, et al. Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: a double- blind, placebo- controlled, randomized trial[J]. Ann Pharmacother, 2015, 49: 953- 961.
[31] Murakami M. Clinical studies of bronchial arterial infusion of CDDP for the treatment of lung cancer: research on the platinum concentration in the tumor and pulmonary parenchyma[J]. Nihon Igaku Hoshasen Gakkai Zasshi, 1989, 49: 880- 891.
[32] Shimizu E, Nakamura Y, Mukai J, et al. Pharmacokinetics of bronchial artery infusion of mitomycin in patients with non- small cell lung cancer[J]. Eur J Cancer, 1991, 27: 1046- 1048.
[33] Furusaka T, Matsuda A, Tanaka A, et al. Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra- arterial chemoradiation therapy with three agents[J]. Acta Otolaryngol, 2013, 133: 318- 326.
[34] 李 辉, 张 洁, 唐 军. 吉西他滨经动脉固定速率泵入治疗晚期胰腺癌的临床使用[J]. 介入放射学杂志, 2016, 25: 506- 509.
[35] 李国平, 龚高全 , 王建华,等. 不可切除的胰腺癌TAI/TACE治疗后回顾性生存分析[J]. 介入放射学杂志, 2015, 24: 118- 123.
[36] Liu F, Tang Y, Sun J, et al. Regional intra- arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta- analysis of randomized controlled trials[J]. PLoS One, 2012, 7: e40847.
[37] Aigner KR, Gailhofer S. Celiac axis infusion and microembolization for advanced stage Ⅲ/Ⅳ pancreatic cancer: a phase Ⅱ study on 265 cases[J]. Anticancer Res, 2005, 25: 4407- 4412.
[38] Avital I. Regional chemotherapy for pancreatic cancer[J]. J Surg Oncol, 2011, 104: 453.
[39] 李长煜, 王小林, 龚高全, 等. 经皮穿肝胆道引流(PTBD)结合经动脉灌注化疗(TAI)治疗胰头癌伴梗阻性黄疸[J]. 复旦学报?医学版, 2014, 41: 222- 226.
[40] 宗 煜, 倪绍祥, 张宪庆. 奥沙利铂经区域性动脉灌注化疗治疗晚期胰腺癌临床分析[J]. 实用药物与临床, 2013, 16: 284- 285.
[41] 薛苏阳, 李佳睿, 张文雷, 等. 应用雷替曲塞行介入治疗结直肠癌肝转移的疗效[J]. 中国老年学杂志, 2014, 34: 2887- 2888.
[42] Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study[J]. Anticancer Drugs, 2010, 21: 656- 661.
[43] 姚 玮, 张君儒, 陈连锁, 等. 雷替曲塞TACE治疗胃癌术后肝转移的近期疗效观察[J]. 介入放射学杂志, 2016, 25: 125- 128.
[44] 刘 鹏, 朱 旭, 杨仁杰, 等. 72例胃癌肝转移化疗后进展的介入治疗的回顾性分析[J]. 介入放射学杂志, 2013, 22: 742- 746.
[45] Kumada T, Arai Y, Itoh K, et al. Phase Ⅱ study of combined administration of 5- fluorouracil, epirubicin and mitomycin- C by hepatic artery infusion in patients with liver metastases of gastric cancer[J]. Oncology, 1999, 57: 216- 223.
[46] Tarazov PG. Transcatheter therapy of gastic cancer metastatic to the liver: preliminary results[J]. J Gastroenterol, 2000, 35: 907- 911.
[47] Yonemura Y, Matuki N, Sakuma H, et al. Effect of intra- hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases[J]. Surg Today, 1992, 22: 253- 259.
[48] Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer[J]. N Engl J Med, 1999, 341: 2039- 2048.
[49] Vitale FV, Romeo P, Luciani B, et al. Mitomycin- based hepatic arterial infusion chemotherapy for solitary ampullary cancer liver metastasis: an unusual treatment for an uncommon disease[J]. J Oncol Pharm Pract, 2015, 21: 396- 399.
[50] Zhao C, Fan L, Qi F, et al. Raltitrexed plus oxaliplatin- based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. Anticancer Drugs, 2016, 27: 689- 694.
[51] 唐 杰, 朱晓黎, 沈 建, 等. 雷替曲塞介入治疗中晚期原发性肝癌的疗效及安全性分析[J]. 临床肿瘤学杂志, 2015, 20: 249- 252.
[52] Cheung AH, Lam CS, Tam HS, et al. Nine- year experience of doxorubicin- eluting beads chemoembolization for hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2016, 15: 493- 498.
[53] 贺红杰, 宋 磊, 赵丹懿, 等. 雷替曲塞联合奥沙利铂经TACE治疗不可切除肝癌患者的疗效评价[J]. 介入放射学杂志, 2016, 25: 40- 43.
[54] Kemeny MM, Adak S, Gray B, et al. Combined- modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy: an intergroup study[J]. J Clin Oncol, 2002, 20: 1499- 1505.
[55] Kemeny N, Jarnagin W, Gonen M, et al. Phase Ⅰ/Ⅱ study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metasatases from colorectal cancer[J]. J Clin Oncol, 2003, 21: 3303- 3309.
[56] Volovat SR, Volovat C, Negru SM, et al. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis[J]. J Chemother, 2016, 28: 235- 241.
[57] Kemeny NE, Chou JF, Boucher TM, et al. Updated long- term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy[J]. J Surg Oncol, 2016, 113: 477- 484.
[58] Cercek A, Boucher TM, Gluskin JS, et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies[J]. J Surg Oncol, 2016, 114: 655- 663.
[59] Furusaka T, Asakawa T, Tanaka A, et al. Efficacy of multidrug superselective intra- arterial chemotherapy(docetaxel, cisplatin and 5- fluorouracil) using the Seldinger technique for tongue cancer[J]. Acta Otolaryngol, 2012, 132: 1108- 1114.
[60] Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5- fluorouracil- cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck[J]. Anticancer Drugs, 2004,15: 331- 340.
[61] Vermorken BJ, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer[J]. N Engl J Med, 2007, 357: 1695- 1704.
[62] 王 帆, 周 石. 舌鳞癌术前超选择舌动脉化疗栓塞的临床应用[J]. 介入放射学杂志, 2015, 24: 873- 875.
[63] 张 靖, 姜 华, 申 刚, 等. 经眼动脉灌注化疗治疗视网膜母细胞瘤临床疗效多因素分析[J]. 介入放射学杂志, 2015, 24: 1062- 1066.
[64] Li M, Zhang J, Wang D, et al. A phase Ⅱ study of intra- arterial chemotherapy of 5- fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer[J]. Anticancer Drugs, 2009, 20: 941- 945.
[65] 邵 鹏, 余新林, 胡 玮, 等. 替吉奥联合奥沙利铂动脉灌注及栓塞治疗晚期胃癌的临床疗效[J]. 中国癌症防治杂志, 2016, 8: 96- 99.
[66] 税明才, 熊 林. 短程EOF方案区域动脉灌注化疗与常规化疗用于进展期胃癌的有效性和安全性评估[J]. 海南医学院院报, 2016, 22: 82- 85.
[67] 孙 宾, 李 兴, 宋 杰, 等. 进展期胃癌术前介入治疗的临床应用[J]. 实用放射学杂志, 2014, 30: 2054- 2057.
[68] Seki H, Ohi H, Ozaki T, et al. Hepatic arterial infusion chemotherapy using fluorouracil, epirubicin, and mitomycin C for patients with liver metastases from gastric cancer after treatment failure of systemic S- 1 plus cisplatin[J]. Acta Radiol,2016, 57: 781- 788.
[69] 高 峰, 黄祥中, 任冬青, 等. 经动脉灌注化疗联合不同化疗方法治疗进展期胃癌60例对照研究[J]. 介入放射学杂志, 2013, 22: 857- 859.
[70] Aigner KR, Thiem N. Regional chemotherapy for recurrent breast cancer: the effect of different techniques of drug administration on tumor response[J]. Reg Cancer Treat, 1994, 7: 127- 131.
[71] Tanigawa T, Hasuike Y, Akiyama Y, et al. Pre- operative treatment with transcatheter arterial chemoembolization (TACE) and hepatic arterial infusion(HAI) for liver metastasis from gastric cancer: a case report[J]. Gan To Kagaku Ryoho, 2015, 42: 1460- 1462.
[72] Stephens FO. Intraarterial induction chemotherapy in locally advanced stage Ⅲ breast cancer[J]. Cancer, 1990, 66: 645- 650.
[73] Fiorentini G, Tsetis D, Bernardeschi P, et al. First- line intra- arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer[J]. Anticancer Res, 2003, 23:4339- 4345.
[74] Elias D, Maisonnette F, Druet- Cabanac M, et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer[J]. Am J Surg, 2003, 185: 158- 164.
[75] Cantore M1, Fiorentini G, Cavazzini G, et al. Four years experience of primary intra- arterial chemotherapy(PIAC) for locally advanced and recurrent breast cancer[J]. Minerva Chir, 1997, 52: 1077- 1082.
[76] Fiorentini G1, Tsetis D, Bernardeschi P, et al. First- line intra- arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer[J]. Anticancer Res, 2003, 23:4339- 4345.
[77] 张 远, 庞伟强, 陈益红. 经导管动脉内温热化疗治疗卵巢癌疗效评估[J]. 实用放射学杂志, 2005, 21: 739- 742.
[78] 孙 勇, 倪才方, 刘一之. 肠系膜下动脉在晚期卵巢癌及其术后复发介入治疗中的价值[J]. 介入放射学杂志, 2017, 26: 305- 307.
[79] 朱元方, 司马妮, 蔡丽萍. 卵巢癌介入化疗和腹腔静脉双途径化疗疗效观察[J]. 南昌大学学报, 2003, 5: 64- 66.
[80] Seki A, Hori S, Sueyoshi S, et al. Local control and prognostic significance of transarterial treatment for limited recurrence of ovarian cancer as third- line and beyond therapy[J]. Int J Clin Oncol, 2014, 19: 1065- 1073.
[81] 杨学刚, 周 石, 李政文, 等. 不同途径新辅助化疗治疗年轻宫颈癌的疗效比较[J]. 介入放射学杂志, 2015, 24: 342- 346.
[82] 郑 宇, 张学军, 朝鲁孟, 等. 子宫动脉灌注化疗对Ib~IIb期宫颈癌疗效的临床观察[J]. 实用放射学杂志, 2014, 30: 1546- 1548.
[83] 蒋天鹏, 杨学刚, 许国辉, 等. 宫颈癌(IIB~IIIB期)动脉灌注化疗栓塞的临床疗效研究[J]. 实用放射学杂志, 2015, 31: 293- 295.
[84] 包 影, 李楷滨. 宫颈癌的新辅助动脉化疗[J]. 实用妇产科杂志, 2003, 19: 208- 210.
[85] 曹 野, 佐满珍, 陈 华, 等. 超选择性子宫动脉化疗栓塞在巨大宫颈癌治疗中的价值[J]. 实用妇产科杂志, 2010, 26: 513- 515.
[86] 盛晓艳, 骆 佳. 多西他赛联合顺铂不同化疗途径治疗宫颈癌的临床疗效对比观察[J]. 河北医学, 2012, 18: 1073- 1075.
[87] 邹俊民, 龙世娟, 张振明. 改良髂内动脉化疗联合放疗治疗Ⅲ~Ⅳa期子宫颈癌32例[J]. 介入放射学杂志, 2012, 21: 123- 126.
[88] Kobayashi K, Furukawa A, Takahashi M, et al. Neoadjuvant intra- arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response[J]. Cardiovasc Intervent Radiol, 2003, 26: 234- 241.
[89] Zhao EF, Bao L, Li C, et al. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years[J]. J First Mil Med Univ, 2005, 25: 605- 609.
[90] Nagata Y, Araki N, Kimura H, et al. Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cervical cancer[J]. J Vasc Interv Radiol, 2000, 11: 313- 319.
[91] Motoyama S, Hamana S, Ku Y, et al. Neoadjuvant high- dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages Ⅲa- Ⅳa cervical cancer[J]. Gynecol Oncol, 2004, 95:576- 582.
[92] Sardi JE, Boixadera MA, Sardi JJ. Neoadjuvant chemotherapy in cervical cancer: a new trend[J]. Curr Opin Obstet Gynecol,2005, 17: 43- 47.
[93] Kobayashi K, Furukawa A, Takahashi M, et al. Neoadjuvant intra- arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response[J].Cardiovasc Intervent Radiol, 2003, 26: 234- 241.
[94] 朱雪琼, 岳天孚, 张 颖. 新辅助动脉化疗对子宫内膜癌细胞凋亡和耐药性的影响[J]. 中国肿瘤临床, 2002, 29: 701- 706.
[95] 朱雪琼, 岳天孚, 王德华. 术前介入化疗在子宫内膜癌的应用及对手术的影响[J]. 介入放射学杂志, 2001, 28: 143- 145.
[96] 薛月珍, 李芬朱, 佩 英. 超选择动脉插管化疗在治疗妇科中晚期恶性肿瘤中的应用[J]. 肿瘤研究与临床, 2004, 16: 35- 36.
[97] 童 强, 姚立欣, 黄金明, 等. 髂内动脉化疗栓塞联合经尿道膀胱肿瘤电切术治疗晚期膀胱癌17例[J]. 介入放射学杂志, 2013, 22: 148- 150.
[98] 孙 昊, 李晓光, 金征宇. 经导管双侧髂内动脉灌注化疗治疗浸润性膀胱癌[J]. 介入放射学杂志, 2010, 19: 454- 457.
[99] 王 健, 邹英华, 蒋学祥. 经导管动脉灌注化疗治疗膀胱癌的研究[J]. 介入放射学杂志, 1999, 8: 25- 27.
[100] Chen J, Yao Z, Qiu S, et al. Comparing intra- arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinomaafter bladder- preserving surgery[J]. Cardiovasc Intervent Radiol, 2013, 36: 1521- 1526.
[101] Ganaha F, Yamada T, Ujita M, et al. Intraarterial low- dose cisplatin via an indwelling portand concurrent radiotherapy for invasive bladder cancer[J]. J Vasc Interv Radiol, 2001, 12: 379- 384.
[102]周际昌. 实用肿瘤内科治疗[M]. 北京: 北京科学技术出版社, 2013: 433.
[103] 姚 阳, 林 峰, 汤丽娜, 等. IIB期肢体骨肉瘤综合治疗的临床疗效分析[J]. 中国癌症杂志, 2008, 18: 286- 290.
[104] 余文熙, 林 峰, 姚 阳. 95例IIB肢体骨肉瘤生存分析——新辅助化疗结合区域动脉灌注疗效探讨[J]. 中国骨肿瘤骨病, 2009, 8: 65- 69.
[105] 欧阳墉. 经导管动脉灌注术和栓塞术在我国的发展历程及其现状[J]. 介入放射学杂志, 2008, 17: 892- 897.
[106]Hannani D, Locher C, Yamazaki T, et al. Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines[J]. Cell Death Differ, 2014, 21: 50- 58.
[107] Ito A, Shintaku I, Satoh M, et al. Prospective randomized phaseⅡtrial of a single early intravesical instillation of pirarubicin(THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial[J]. J Clin Oncol, 2013, 31: 1422- 1427.
[108] Qi WX, He AN, Tang LN, et al. Evaluation of pirarubicin- cisplatin chemotherapy in the treatment for refractory and recurrent high- grade osteosarcoma: experience of a single institute[J]. Med Oncol, 2012, 29: 2229- 2233.
[109]Yonemoto T, Hosono A, Iwata S, et al. The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan[J].Int J Clin Oncol, 2015, 20: 613- 616.
[110]Yu W, Tang L, Lin F, et al. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high- grade osteosarcoma: does the analog matter?[J]. Med Oncol, 2015, 32: 307.
[111] 董汉彬, 郭 攻. 结肠癌C期术后动脉灌注化疗的临床观察[J]. 广东药学院学报, 2002, 18: 255- 256.
[112]帅鲁静, 刘文志, 张 旭, 等. CME联合术中动脉灌注及腹腔内间质缓释剂化疗的研究[J]. 中国肿瘤临床, 2013, 40: 1460- 1463.
[113]丁小兵, 李玉梅, 邹叶青. 新辅助化疗、术中灌注化疗对结直肠癌患者VEGF的影响[J]. 实用癌症杂志, 2016, 31: 1678- 1682.
[114]刘德华, 魏 宏, 王少雷, 等. 结直肠癌根治术前应用肝动脉联合区域动脉灌注化疗对患者预后的影响[J]. 疑难病杂志, 2016, 15: 1040- 1047.
[115]戚 诚, 赵晓东, 闫长青, 等. 雷替曲塞动脉灌注化疗对肝转移癌的疗效及其对血浆血管内皮细胞生长因子和甲胎蛋白水平的影响[J]. 中华实验外科杂志, 2015, 32: 1150- 1151.
[116]弥海宁, 何科基, 杨言苹, 等. 进展期结直肠癌动脉灌注新辅助化疗临床疗效观察[J]. 中国综合临床, 2011, 27: 417- 420.
[117]Bini R, Comelli S, Addeo A, et al. Inferior mesenteric artery chemoembolization and chemotherapy for advanced rectal cancer: report of a clinical case[J]. Tumori, 2015, 101: e82- e84.

相似文献/References:

[1]方世明,李海利,林   青,等. X线引导下鼻肠梗阻导管插入引流治疗不能手术的恶性肠梗阻[J].介入放射学杂志,2011,(12):979.
 FANG Shi-ming,LI Hai-li,LIN Qing,et al.Fluoroscopically-guided transnasal insertion of ileus tube for intestinal decompression in patients with inoperable malignant bowel obstruction[J].journal interventional radiology,2011,(11):979.
[2]邓美香,金泳海,倪才方,等.植入支架治疗恶性肿瘤压迫致髂静脉狭窄14例[J].介入放射学杂志,2014,(02):118.
 DENG Mei? xiang,JIN Yong? hai,NI Cai? fang,et al. Stent implantation for iliac vein stenosis caused by malignant tumor compression: analysis of 14 cases [J].journal interventional radiology,2014,(11):118.
[3]魏 宁,陈启鸿,徐 浩,等.通气导管辅助下125I支架置入术治疗恶性气道狭窄24例 [J].介入放射学杂志,2017,(12):1118.
 WEI Ning,CHEN Qihong,XU Hao,et al.Treatment of malignant airway stenosis with 125I seed stent implantation assisted by airway tube: preliminary results in 24 patients[J].journal interventional radiology,2017,(11):1118.
[4]解旭品,方 欣,黄昌拼,等.血管内支架治疗恶性肿瘤引起的上腔静脉综合征疗效分析 [J].介入放射学杂志,2019,28(05):436.
 XIE Xupin,FANG Xin,HUANG Changpin,et al.Endovascular stenting for the treatment of superior vena cava syndrome caused by malignant tumors: analysis of its curative effect[J].journal interventional radiology,2019,28(11):436.
[5]张燕,刘楠,任培蓉,等.自制定位器引导模板辅助PET分子成像定向肺活检术 [J].介入放射学杂志,2020,29(03):300.
 ZHANG Yan,LIU Nan,REN Peirong,et al.Self-made locator guiding template-assisted PET molecular imaging–directed lung biopsy[J].journal interventional radiology,2020,29(11):300.
[6]胡章明,李坤峰,姚宜斌,等.胆道支架联合125I粒子条对恶性梗阻性黄疸的治疗效果[J].介入放射学杂志,2020,29(01):59.
 HU Zhangming,LI Kunfeng,YAO Yibin,et al.Biliary stenting combined with 125I seed strip implantation for the treatment of malignant obstructive jaundice: analysis of curative effect[J].journal interventional radiology,2020,29(11):59.
[7]赵开飞,谭瑞,利峰,等.以下肢深静脉血栓为首发症状的恶性肿瘤患者28例临床分析[J].介入放射学杂志,2020,29(02):186.
 ZHAO Kaifei,TAN Rui,LI Feng,et al. Malignant tumor with deep venous thrombosis as its initial manifestation: report of 28 patients[J].journal interventional radiology,2020,29(11):186.
[8]赵开飞,谭?瑞,利?峰,等.以下肢深静脉血栓为首发症状的恶性肿瘤患者28例临床分析[J].介入放射学杂志,2020,29(02):191.
 ZHAO Kaifei,TAN Rui,LI Feng,et al.Malignant tumor with deep venous thrombosis as its initial manifestation: report of 28 patients[J].journal interventional radiology,2020,29(11):191.

备注/Memo

备注/Memo:
(收稿日期:2017-06-26)
(本文编辑:边 佶)
更新日期/Last Update: 2017-11-16